Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Lexeo Therapeutics, Inc. (LXEO : NSDQ)

• Company Description    Lexeo Therapeutics is a clinical-stage genetic medicine company which defined cardiovascular diseases and APOE4-associated Alzheimer's disease are treated. Lexeo Therapeutics is based in New York City. Number of Employees: 72

• Price / Volume Information    Yesterday's Closing Price: $4.59 Daily Weekly Monthly 20 Day Moving Average: 489,642 shares Shares Outstanding: 33.20 (millions) Market Capitalization: $152.37 (millions) Beta: 1.32 52 Week High: $18.23 52 Week Low: $1.45 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 12.23% 8.02% 12 Week 69.37% 42.47% Year To Date -30.24% -34.67%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 345 PARK AVENUE SOUTH FLOOR 6 - NEW YORK,NY 10010 USA ph: 212-547-9879 fax: - investors@lexeotx.com http://www.lexeotx.com

• General Corporate Information    Officers R. Nolan Townsend - Chief Executive Officer and Director Kyle Rasbach - Chief Financial Officer Mette Kirstine Agger - Director Steven Altschuler - Director Paula HJ Cholmondeley - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 52886X107 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/11/25 Share - Related Items Shares Outstanding: 33.20 Most Recent Split Date: (:1) Beta: 1.32 Market Capitalization: $152.37 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.52 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.57 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/11/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.73 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -28.57% vs. Previous Quarter: -26.92% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - -85.86 12/31/24 - -65.11 ROA 06/30/25 - - 03/31/25 - -68.48 12/31/24 - -54.18 Current Ratio 06/30/25 - - 03/31/25 - 3.42 12/31/24 - 5.52 Quick Ratio 06/30/25 - - 03/31/25 - 3.42 12/31/24 - 5.52 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - 2.65 12/31/24 - 3.53 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.01 12/31/24 - 0.01 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.79 12/31/24 - 0.69

Powered by Zacks Investment Research ©